L. da Costa

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.

M. Pfreundschuh, F. Hartmann, S. Bauer, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3.

V. Diehl, M. Pfreundschuh, J. Bosq, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines.

M. Pfreundschuh, B. Caillou, J. Lumbroso, 1990, European journal of cancer.

Radiolabeled monoclonal antibodies against Reed-Sternberg cells for in vivo imaging of Hodgkin's disease by immunoscintigraphy.

V. Diehl, M. Pfreundschuh, B. Caillou, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.

V. Diehl, M. Pfreundschuh, D. Hasenclever, 1991, Blood.

[In vivo imaging of Hodgkin's lymphomas using monoclonal antibodies].

V. Diehl, M. Pfreundschuh, B. Caillou, 1989, Onkologie.

Mini Test Dose of Intravenous Busulfan (Busulfex®) in Allogeneic Non-Myeloablative Stem Cell Transplantation, Followed by Liquid Chromatography Tandem-Mass Spectrometry

K. Sullivan, J. Chute, D. Rizzieri, 2011, Cancer investigation.

Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease

M. Pfreundschuh, F. Hartmann, C. Renner, 2000, Cancer Chemotherapy and Pharmacology.